Management of metastatic castration-resistant prostate cancer in Middle East African countries: Challenges and strategic recommendations

Bazarbashi S., Alsharm A., Meshref A., Mrabti H., Ansari J., Ghosn M., ...Daha Fazla

UROLOGY ANNALS, cilt.14, sa.4, ss.303-313, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 14 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4103/ua.ua_148_21
  • Dergi Adı: UROLOGY ANNALS
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, EMBASE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.303-313
  • Anahtar Kelimeler: Genetic testing, metastatic castration-resistant prostate cancer, Middle East African region, multidisciplinary care, MULTIDISCIPLINARY, GUIDELINES, QUALITY, DEFECTS, CARE
  • Ankara Üniversitesi Adresli: Evet

Özet

Despite the reliance on Western guidelines for managing prostate cancer (PC), there are wide variations and gaps in treatment among developing countries such as the Middle East African (MEA) region. A multidisciplinary team of experts from the MEA region engaged in a comprehensive discussion to identify the real-world challenges in diagnostics and treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) and provided insights on the urgent unmet needs. We present a consensus document on the region-specific barriers, key priority areas and strategic recommendations by experts for optimizing management of mCRPC in the MEA. Limited access to genetic testing and economic constraints were highlighted as major concerns in the MEA. As the therapeutic landscape continues to expand, treatment selection for mCRPC needs to be increasingly personalized. Enhanced genetic testing and judicious utilization of newer therapies like olaparib, articulated by reimbursement support, should be made accessible for the underserved populations in the MEA. Increasing awareness on testing through educational activities catalyzed by digital technologies can play a central role in overcoming barriers to patient care in the MEA region. The involvement of multidisciplinary teams can bridge the treatment gaps, facilitating holistic and optimal management of mCRPC. Region-specific guidelines can help health-care workers navigate challenges and deliver personalized management through collaborative efforts - thus curb health-care variations and drive consistency. Development of region-specific scalable guidelines for genetic testing and treatment of mCRPC, factoring in the trade-off for access, availability, and affordability, is crucial.